Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Frederick E. Pierce
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Beta
- 0.56
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -20.01
Financials
Revenue
$0.00-100.0%Net Income
$-2.37MEBITDA
$-2.37MFree Cash Flow
$-2.69MEPS (diluted)
$-4.46Shares Outstanding (diluted)
532.0K+16158.2%Operating Expenses
$2.63MCash & Debt
$8.29MReturn of Capital
$0.00Revenue by Segment (annual)
$2.60MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-12.52M | $-25.99 |
| 2024 | $0.00 | $-5.58M | $-86.92 |
| 2023 | $0.00 | $-12.54M | $-461.04 |
| 2022 | $0.00 | $-31.61M | $-1785.33 |
| 2021 | $0.00 | $-12.77M | $-926.01 |
| 2020 | $5.23M | $-7.35M | $-1415.85 |
| 2019 | $3.47M | $-6.94M | $-6366.21 |
| 2018 | $838.1K | $-21.92M | $-87374.00 |
| 2017 | $1.27M | $-34.43M | $-149250.00 |
| 2016 | $1.01M | $-39.49M | $-182250.00 |
| 2015 | $0.00 | $-29.14M | $-156000.00 |
| 2014 | $0.00 | $-8.01M | $-342750.00 |
Valuation
DCOYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
153+408.33%Social Signal Score
Mentions (3)
- Newsprnewswire.com·20h ago·Neutral
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026 announcing the Company's warrant inducement transaction.
View source ↗ - Newsprnewswire.com·1d ago·Neutral
… and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility CAMBRIDGE, Mass., Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™) to target major respiratory and high consequence viral threats, today announced a refined corporate strategy to explore its D-MAVs for additional candidates, including a pan-filovirus program along the U.S. Food and Drug Administration (FDA) Animal Rule …
View source ↗ - Newsnewsfilecorp.com·15d ago·Negative
…ver an investor presentation on Thursday, September 10 in New York Cambridge, Massachusetts--(Newsfile Corp. - September 8, 2026) - Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across many viruses, today announced that Rick Pierce, Chief Executive Officer, will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9 and 1…
View source ↗
Earnings
Fri, Nov 13(in 7 weeks)
Consensus estimate $-3.12 per share
Typical surprise +96.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-4.46 vs $-2.88miss
- Wed, May 13$-4.18 vs $-4.12miss
- Fri, Apr 3$-18.64 vs $-6.48miss
- Fri, Nov 14$-1.81 vs $-403.20beat
- Mon, Aug 11$-6.75 vs $-396.00beat
- Wed, May 14$-15.44 vs $-432.00beat
Estimates and results for DCOY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DCOY officers and directors.
- Bought
- $176k
- Sold
- $17
23 trades
2 trades
- Hanish Arnold Csold
- Hanish Arnold Csold
- Hanish Arnold Cbought
- Rosenblum Mark Jbought
- Burleson Tessbought
- Lieber Jonathan Ibought
- Mcvicar William K.bought
- Hanish Arnold Cbought
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DCOY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.